The diabetes and weight-loss medications semaglutide and tirzepatide—marketed as Ozempic, Wegovy, Mounjaro, and Zepbound—may help preserve thinking skills in certain patients, even though semaglutide did not slow early Alzheimer’s disease in two large clinical trials, according to a new review published in the journal Science. The analysis, conducted by researchers at the University of Gothenburg in Sweden and the University of Copenhagen in Denmark, was summarized by ScienceDaily this week.
The review presents no new experimental data. Instead, it evaluates existing evidence that divides sharply by category. Animal studies indicate that GLP-1 drugs can affect learning and memory. In humans, the findings are less consistent, and the only large randomized trials involving Alzheimer’s patients produced negative results.
This distinction matters for millions of households. Many people taking these medications, along with adult children caring for parents experiencing memory loss, have encountered headlines linking GLP-1 drugs to dementia. The review does not endorse using these drugs to treat or prevent Alzheimer’s, and none are currently approved for that purpose.
Animal Signals Versus Human Evidence
The strongest indications come from laboratory animals, where GLP-1 drugs have been shown to influence learning and memory. The University of Gothenburg’s announcement does not specify the species, dosages, or methodologies underlying those studies, and animal findings frequently do not translate to humans.
Human evidence appears in two forms. Analyses of patient health records have associated GLP-1 treatment with a reduced dementia risk among people with type 2 diabetes. However, these studies are observational and cannot establish whether the drugs caused the lower risk or whether recipients differed in other respects, such as general health or access to care.
Randomized trials provide a clearer answer for Alzheimer’s. Novo Nordisk’s EVOKE and EVOKE+ trials tested once-daily oral semaglutide, up to 14 mg, against a placebo added to standard care in 3,808 adults with early Alzheimer’s. Participants ranged from 55 to 85 years old and had mild cognitive impairment or mild dementia due to Alzheimer’s. Semaglutide did not slow cognitive decline, according to results published in The Lancet, although it altered several Alzheimer’s-related biomarkers.
Novo Nordisk had acknowledged the long odds. When announcing the results in November 2025, research chief Martin Holst Lange stated that the company “felt we had a responsibility to explore semaglutide’s potential, despite a low likelihood of success.”
Smaller studies leave the question open. A small Phase 2b trial of liraglutide, an older GLP-1 medication, found indications of slower cognitive decline in people with Alzheimer’s, Science News reported. Its limited size means it cannot resolve the issue.
Attention, Planning, and the Metabolic Connection
The review’s authors argue that the trial failure does not rule out benefits for other patient groups. People with obesity or type 2 diabetes often experience difficulties with attention, planning, and processing speed—issues the authors say are frequently linked to metabolism and vascular health rather than Alzheimer’s-related brain changes. Those problems, they suggest, may respond better to treatment.
“We need to find out whether these treatments can help people with obesity or diabetes preserve their cognitive abilities,” said first author Stina Börchers, a researcher at the University of Gothenburg. The authors also emphasize the need to identify which patients might benefit.
How the drugs might work remains the central unknown. They could support the brain indirectly through improved blood sugar, blood pressure, and weight, directly through effects on the brain, or both. Senior author Christoffer Clemmensen of the University of Copenhagen said separating these effects could eventually lead to treatments specifically designed to preserve cognitive function.
Evidence Check
This is an invited review in Science, not a new study. Its human evidence includes observational record studies, which cannot prove causation, and two randomized trials involving 3,808 people that found no slowing of early Alzheimer’s. Animal findings suggest effects on memory and learning, but no clinical benefit has been confirmed in people. The review does not change medical guidance, and funding details were not listed in the university’s announcement.
Considerations for Older Adults, Caregivers, and Treatment Choices
The authors highlight a specific risk for older and frail patients, the group most likely to inquire about memory protection. Rapid weight loss can reduce muscle mass, potentially weakening physical function and offsetting some possible benefits of treatment. For a caregiver, that could mean more falls or less independence rather than improved memory.
People already taking a GLP-1 drug for diabetes, weight management, or heart protection should not stop or change their medication based on this review without consulting their prescriber. Starting one solely to protect memory is not supported by current evidence, and insurance coverage is generally tied to approved uses such as diabetes and obesity, not cognition.
Anyone noticing memory changes in themselves or a relative can begin with a primary care clinician, who can screen for treatable causes such as thyroid problems, vitamin B12 deficiency, sleep apnea, or medication side effects. Sudden confusion, weakness, or trouble speaking requires emergency care.
The researchers are calling for clinical trials that track memory and other thinking skills from the outset of GLP-1 treatment. Such trials could determine whether these drugs protect everyday cognition rather than slow a specific brain disease.
Key Questions Answered
What did the Science review say? GLP-1 drugs may affect brain function and could help some people with obesity or diabetes preserve attention and planning skills, but this has not been proven in people.
Did semaglutide slow Alzheimer’s? No. The EVOKE and EVOKE+ trials of 3,808 people found no slowing of early Alzheimer’s.
What do animal studies show? They suggest GLP-1 drugs can influence learning and memory, but animal results do not prove benefit in people.
Do GLP-1 drugs prevent dementia? Some studies link them to lower dementia risk in people with diabetes, but they cannot prove the drugs caused it.
Should I take Ozempic to protect my memory? No current evidence supports that, and the drugs are not approved for cognitive protection.
Also Read
- Massive Abdominal Cyst Misdiagnosed as Cancer Turns Out to Be Lymphatic Filariasis
- NHS England Faces Scrutiny After 3,000 Patient Record Snooping Cases
- A Two-Week Nosebleed Defied Treatment Until Doctors Uncovered a Live Leech Inside a Man’s Nose
- Viz.ai Embeds UpToDate Expert AI Into Care Coordination Platform to Accelerate Clinical Decision-Making


